Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
RegulatoryWatchMinormateriality 56 out of 100
What happened
FactPendency of Litigation(s)/dispute(s) or the outcome impacting the Company.
Why it matters
CapitSignal interpretationLitigation creates a contingent liability that is not in reported profit until it crystallises.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedEarlierQ1 FY27
excluding the ibuprofen business, the base business delivered a 24% growth on this quarter.
NowQ1 FY27
if you adjust that particular price increase what we had passed through in terms of revenue growth number, so that growth should be coming around to close to 18%, 19% of year-on-year growth as compared to Q1 of '26.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved -25.00%.confidence 60%
Watch next
Fact- Amount claimed against the company
- Whether a provision has been made
- Next hearing or order date
- the strategic review of the ibuprofen business would be concluded by the first half of '27. (management committed by H1 FY27)
- we will come up with the next steps in terms of both ibuprofen Vizag, Pondy and what we do with the CRAMS deme (management committed by Q2 FY27)
Evidence
- Solara Active Pharma Sciences Limited has informed the Exchange about the receipt of Demand Notice from the Income Tax Authorities.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- LITIGATION base 56; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%